Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma

Straka, Christian and Salwender, Hans and Schnabel, Brigitte and Sandherr, Michael and Wandt, Hannes and Huebel, Kai and Scheid, Christof and Metzner, Bernd and Hentrich, Marcus and Franke, Daniel and Weidenegger, Gloria and Freund, Mathias and Sezer, Orhan and Einsele, Hermann and Hinke, Axel and Emmerich, Bertold (2015) Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma. LEUKEMIA & LYMPHOMA, 56 (2). pp. 368-376. ISSN 1042-8194, 1029-2403

Full text not available from this repository. (Request a copy)

Abstract

The patient granulocyte-colony stimulating factor (G-CSF) response is represented by the leukocyte peak in the blood induced by a single dose of G-CSF after chemotherapy, and is correlated with subsequent neutropenic infection risk. General patterns for a meaningful risk group stratification, have not yet been determined. Two independent data sets including a total of 306 cases with myeloma or lymphoma and autologous blood stem cell transplant were available. An infection susceptibility curve plotted according to ranked G-CSF responses from a multicenter study reproduced and validated a curve from the previous single center. Two trend changes were seen within these curves at around 11 000 and 22 000 leukocytes/mu L, which separated three groups with a high, medium and low risk of infection. While G-CSF response is related to the consecutive duration of neutropenia, it retains additional independent predictive information for infection risk (p < 0.0001) and, more important, is a tool available before the onset of the critical period.

Item Type: Article
Uncontrolled Keywords: STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; CLINICAL-PRACTICE GUIDELINE; DIAGNOSED MULTIPLE-MYELOMA; AUTOLOGOUS TRANSPLANTATION; INDUCTION THERAPY; RANDOMIZED-TRIAL; GROWTH-FACTORS; 2010 UPDATE; LENALIDOMIDE; G-CSF; multiple myeloma; lymphoma; neutropenic infection; autologous transplant
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Depositing User: Dr. Gernot Deinzer
Date Deposited: 25 Jul 2019 07:15
Last Modified: 25 Jul 2019 07:15
URI: https://pred.uni-regensburg.de/id/eprint/6028

Actions (login required)

View Item View Item